AMNEAL PHARMACEUTICALS, INC. Payments of Financing Costs
AMNEAL PHARMACEUTICALS, INC. (AMRX) reported Payments of Financing Costs of $1.98 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsOfFinancingCosts · last filed 2026-08-06
- AMNEAL PHARMACEUTICALS, INC. payments of financing costs for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- AMNEAL PHARMACEUTICALS, INC. payments of financing costs for the quarter ending 2026-03-31 was $1.98M.
- AMNEAL PHARMACEUTICALS, INC. payments of financing costs for the quarter ending 2025-09-30 was $73.23M.
- AMNEAL PHARMACEUTICALS, INC. payments of financing costs for the quarter ending 2025-06-30 was $1.75M.
- AMNEAL PHARMACEUTICALS, INC. payments of financing costs for fiscal 2023 was $162.41M, a 9666.39% increase from fiscal 2022.
- AMNEAL PHARMACEUTICALS, INC. payments of financing costs for fiscal 2022 was $1.66M.
- AMNEAL PHARMACEUTICALS, INC. payments of financing costs for fiscal 2021 was $0.00, a 100.00% decline from fiscal 2020.
- AMNEAL PHARMACEUTICALS, INC. payments of financing costs for fiscal 2020 was $4.10M.
| Period end | Payments of Financing Costs 3 month | Payments of Financing Costs 6 month | Payments of Financing Costs 9 month | Payments of Financing Costs 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $1.98M 10-Q · filed 2026-08-06 | ||
| 2026-03-31 | $1.98M 10-Q · filed 2026-05-07 | |||
| 2025-09-30 | $73.23M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $74.97M derived: sum of 2 quarters · filed 2026-08-06 | $74.97M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $1.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $1.75M 10-Q · filed 2026-08-06 | ||
| 2025-03-31 | $0.00 10-Q · filed 2026-05-07 | |||
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $0.00 10-Q · filed 2025-11-06 | ||
| 2024-06-30 | $0.00 10-Q · filed 2025-08-07 | |||
| 2023-12-31 | $161.87M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $162.41M derived: sum of 2 quarters · filed 2024-11-12 | $162.41M 10-K · filed 2024-03-14 | |
| 2023-09-30 | $542.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $542.00K 10-Q · filed 2024-11-12 | ||
| 2023-06-30 | $0.00 10-Q · filed 2023-08-08 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $41.00K derived: sum of 2 quarters · filed 2024-03-14 | $1.66M 10-K · filed 2024-03-14 | |
| 2022-09-30 | $41.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $1.66M 10-Q · filed 2023-11-09 | ||
| 2022-06-30 | $1.62M 10-Q · filed 2023-08-08 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $0.00 derived: sum of 2 quarters · filed 2024-03-14 | $0.00 10-K · filed 2024-03-14 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $0.00 10-Q · filed 2022-11-07 | ||
| 2021-06-30 | $0.00 10-Q · filed 2022-08-08 | |||
| 2020-12-31 | $4.10M 10-K · filed 2023-03-03 | |||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $0.00 derived: sum of 2 quarters · filed 2022-03-01 | $0.00 10-K · filed 2022-03-01 | |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | $0.00 10-Q · filed 2019-11-07 | ||
| 2019-06-30 | $0.00 10-Q · filed 2019-08-05 | |||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $0.00 derived: sum of 2 quarters · filed 2021-03-01 | $54.95M 10-K · filed 2021-03-01 | |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | $54.95M 10-Q · filed 2019-11-07 | ||
| 2018-06-30 | $54.95M 10-Q · filed 2019-08-05 | |||
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | $137.00K derived: sum of 2 quarters · filed 2020-03-02 | $5.03M 10-K · filed 2020-03-02 | |
| 2017-09-30 | $137.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | $5.03M 10-Q · filed 2018-11-07 | ||
| 2017-06-30 | $4.89M 10-Q · filed 2018-08-09 | |||
| 2016-12-31 | $6.51M 10-K · filed 2019-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |